IS2212B - 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyrarramide - Google Patents

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyrarramide

Info

Publication number
IS2212B
IS2212B IS5725A IS5725A IS2212B IS 2212 B IS2212 B IS 2212B IS 5725 A IS5725 A IS 5725A IS 5725 A IS5725 A IS 5725A IS 2212 B IS2212 B IS 2212B
Authority
IS
Iceland
Prior art keywords
isobutyrarramide
trifluoromethylphenyl
morpholin
pyridin
tolyl
Prior art date
Application number
IS5725A
Other languages
English (en)
Icelandic (is)
Other versions
IS5725A (is
Inventor
Maria Ballard Theresa
Andrew Higgins Guy
Hoffmann Torsten
Maria Poli Sonia
Sleight Andrew
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of IS5725A publication Critical patent/IS5725A/is
Publication of IS2212B publication Critical patent/IS2212B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IS5725A 1999-11-29 2000-11-24 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyrarramide IS2212B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (2)

Publication Number Publication Date
IS5725A IS5725A (is) 2001-05-29
IS2212B true IS2212B (is) 2007-02-15

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5725A IS2212B (is) 1999-11-29 2000-11-24 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyrarramide

Country Status (49)

Country Link
EP (1) EP1103545B1 (en:Method)
JP (1) JP3480835B2 (en:Method)
KR (1) KR100390117B1 (en:Method)
CN (1) CN1152016C (en:Method)
AR (1) AR033659A1 (en:Method)
AT (1) ATE253561T1 (en:Method)
AU (1) AU775292B2 (en:Method)
BG (1) BG64622B1 (en:Method)
BR (1) BRPI0005616B8 (en:Method)
CA (1) CA2326529C (en:Method)
CO (1) CO5251405A1 (en:Method)
CZ (1) CZ299286B6 (en:Method)
DE (2) DE60006340T2 (en:Method)
DK (1) DK1103545T3 (en:Method)
DO (1) DOP2000000106A (en:Method)
EA (1) EA004404B1 (en:Method)
ES (2) ES2208205T3 (en:Method)
FR (1) FR2801590A1 (en:Method)
GB (1) GB2356863A (en:Method)
GC (1) GC0000151A (en:Method)
GE (1) GEP20022763B (en:Method)
GT (1) GT200000197A (en:Method)
HR (1) HRP20000809A2 (en:Method)
HU (1) HU224703B1 (en:Method)
ID (1) ID28483A (en:Method)
IL (1) IL139868A (en:Method)
IS (1) IS2212B (en:Method)
IT (1) IT1320120B1 (en:Method)
JO (1) JO2298B1 (en:Method)
MA (1) MA26754A1 (en:Method)
MX (1) MXPA00011672A (en:Method)
MY (1) MY127426A (en:Method)
NO (1) NO317264B1 (en:Method)
NZ (1) NZ508386A (en:Method)
OA (1) OA11513A (en:Method)
PA (1) PA8507201A1 (en:Method)
PE (1) PE20010901A1 (en:Method)
PL (1) PL195957B1 (en:Method)
PT (1) PT1103545E (en:Method)
SG (1) SG97171A1 (en:Method)
SI (1) SI1103545T1 (en:Method)
SK (1) SK285373B6 (en:Method)
SV (1) SV2002000227A (en:Method)
TN (1) TNSN00226A1 (en:Method)
TR (1) TR200302077T4 (en:Method)
UA (1) UA70326C2 (en:Method)
UY (1) UY26458A1 (en:Method)
YU (1) YU73400A (en:Method)
ZA (1) ZA200006964B (en:Method)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
ES2272264T3 (es) * 1999-02-24 2007-05-01 F. Hoffmann-La Roche Ag Derivados de fenilo y piridinilo como antagonistas de neuroquinina 1.
EP1303490B1 (en) * 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
IL162733A0 (en) * 2002-01-31 2005-11-20 Hoffmann La Roche Genetic polymorphisms in the preprotachykinin gene
WO2005002577A1 (en) 2003-07-03 2005-01-13 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
WO2006002860A1 (en) 2004-07-06 2006-01-12 F. Hoffmann-La Roche Ag Process for preparing carboxamide pyridine derivatives used as intermediates in the synthesis of nk-1 receptor antagonists
CN101128189A (zh) 2005-02-25 2008-02-20 弗·哈夫曼-拉罗切有限公司 药物物质分散性改善的片剂
PT1863767E (pt) * 2005-03-23 2009-03-27 Hoffmann La Roche Metabolitos para antagonistas de nk-1 para vómitos
ES2335922T3 (es) * 2005-09-23 2010-04-06 F.Hoffmann-La Roche Ag Nueva formulacion de dosificacion.
KR20090112722A (ko) 2007-01-24 2009-10-28 글락소 그룹 리미티드 3,5-디아미노-6-(2,3-디클로로페닐)-1,2,4-트리아진 또는 ｒ(-)-2,4-디아미노-5-(2,3-디클로로페닐)-6-플루오로메틸 피리미딘 및 ｎｋ1을 포함하는 제약 조성물
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
ES2890077T3 (es) 2013-03-15 2022-01-17 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de la hemoglobina
ES2671418T3 (es) 2013-11-08 2018-06-06 Kissei Pharmaceutical Co., Ltd. Derivado de carboximetilpiperidina
MX361810B (es) 2014-02-07 2018-12-14 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isop ropil-1h-pirazol-5-il-)piridin-3-il)metoxi)benzaldehido.
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0533280B2 (en) * 1991-09-20 2004-12-01 Glaxo Group Limited Novel medical use for tachykinin antagonists
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ATE364606T1 (de) * 1993-12-29 2007-07-15 Merck Sharp & Dohme Substituierte morpholinderivate und ihre verwendung als arzneimittel
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
TW394773B (en) * 1995-03-24 2000-06-21 Takeda Chemical Industries Ltd Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
PT1035115E (pt) * 1999-02-24 2005-01-31 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
EP1303490B1 (en) * 2000-07-14 2008-07-09 F. Hoffmann-La Roche Ag N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
BRPI0005616B8 (pt) 2021-07-06
HU224703B1 (en) 2006-01-30
EA200001114A2 (ru) 2001-08-27
SK285373B6 (sk) 2006-12-07
GC0000151A (en) 2005-06-29
EA004404B1 (ru) 2004-04-29
NZ508386A (en) 2003-02-28
BG64622B1 (bg) 2005-09-30
ZA200006964B (en) 2001-06-05
DE60006340T2 (de) 2004-09-09
DE10058310A1 (de) 2001-05-31
GEP20022763B (en) 2002-08-26
DE60006340D1 (de) 2003-12-11
PE20010901A1 (es) 2001-09-20
AR033659A1 (es) 2004-01-07
HUP0004725A2 (hu) 2002-04-29
PA8507201A1 (es) 2002-02-21
NO20006012L (no) 2001-05-30
BG104992A (en) 2001-11-30
SK17932000A3 (sk) 2001-11-06
FR2801590A1 (fr) 2001-06-01
JP2001151754A (ja) 2001-06-05
DOP2000000106A (es) 2002-07-30
CZ299286B6 (cs) 2008-06-04
ID28483A (id) 2001-05-31
GB2356863A (en) 2001-06-06
IL139868A (en) 2009-09-01
MY127426A (en) 2006-11-30
AU7178700A (en) 2001-05-31
NO317264B1 (no) 2004-09-27
KR100390117B1 (ko) 2003-07-04
MA26754A1 (fr) 2004-12-20
UA70326C2 (en) 2004-10-15
EA200001114A3 (ru) 2001-12-24
BRPI0005616B1 (pt) 2017-12-12
CN1297888A (zh) 2001-06-06
BR0005616A (pt) 2001-07-17
PT1103545E (pt) 2004-03-31
CO5251405A1 (es) 2003-02-28
JO2298B1 (en) 2005-09-12
HK1036759A1 (en) 2002-01-18
TNSN00226A1 (fr) 2002-05-30
SI1103545T1 (en) 2004-02-29
IS5725A (is) 2001-05-29
HU0004725D0 (en:Method) 2001-02-28
SV2002000227A (es) 2002-02-05
ES2208205T3 (es) 2004-06-16
CA2326529C (en) 2009-12-22
OA11513A (fr) 2004-02-03
GT200000197A (es) 2002-05-22
ES2171134A1 (es) 2002-08-16
MXPA00011672A (es) 2002-08-20
ATE253561T1 (de) 2003-11-15
JP3480835B2 (ja) 2003-12-22
IT1320120B1 (it) 2003-11-18
PL195957B1 (pl) 2007-11-30
GB0028566D0 (en) 2001-01-10
YU73400A (sh) 2003-02-28
CN1152016C (zh) 2004-06-02
EP1103545B1 (en) 2003-11-05
NO20006012D0 (no) 2000-11-28
HRP20000809A2 (en) 2001-12-31
IL139868A0 (en) 2002-02-10
SG97171A1 (en) 2003-07-18
CA2326529A1 (en) 2001-05-29
CZ20004399A3 (cs) 2001-07-11
PL344147A1 (en) 2001-06-04
EP1103545A1 (en) 2001-05-30
DK1103545T3 (da) 2004-03-15
AU775292B2 (en) 2004-07-29
KR20010051983A (ko) 2001-06-25
TR200302077T4 (tr) 2004-01-21
UY26458A1 (es) 2001-05-31
ITMI20002575A1 (it) 2002-05-29

Similar Documents

Publication Publication Date Title
IS2212B (is) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyrarramide
EP1174509A4 (en) cytidine deaminase
PT1056759E (pt) Derivados do 2-(purin-9-il)-tetrahidrofurano-3,4-diolc
DE60003375D1 (de) Augenpolster
DE69907964D1 (de) 1,2-annelierte chinolinderivate
ID29609A (id) Turunan 2-(purin-9-il)-tetrahidrofuran-3,4-diol
ID27265A (id) Popok sekali pakai
ID28219A (id) Turunan 2-(purin-9-il) -tetrahidrofuran-3,4-diol
ID26457A (id) Popok sekali pakai
ID27095A (id) Popok sekali pakai
ID28132A (id) Popok sekali pakai
FR2806720B1 (fr) Derives de 2,2,6,6-diethyl-dimethyl-1-alcoxypiperidines et 1-oxydes correspondants
ATE303388T1 (de) Substituierte 2-pyridinyl-6,7,8,9- tetrahydropyrimidoc1,2-aöpyrimidin-4-on- und 7- pyridinyl-2,3-dihydroimidazo-c1,2-aöpyrimidin- 5(1h)onderivate
ATE338021T1 (de) Substituierte 2-dialkylaminoalkylbiphenyl- derivate
PT1237857E (pt) Novos derivados fenalquiloxi-fenilo
PT1171440E (pt) 3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases
AR028357A1 (es) 4-bencil-1-[2-(4-hidroxi-fenoxi)-etil]-piperidin-3,4-diol
ID28504A (id) Popok sekali pakai
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
ID26456A (id) Popok sekali pakai
DE60025958D1 (de) 14,15-beta-methylen substituierte androgene
NO20040404L (no) 2- (3,5-bis-trifluorometyl-fenyl) - N - [6-(1,1-diokso-1lam bda6-tiomorfolin-4-yl) - 4 - (2-metyl- eller 4-fluor-2-metylsubstituert) fenyl-pyridin-3-yl] -N-metyl-isobutyrami.
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
NO20030868L (no) N-(3,5-diklor-2-metoksyfenyl)-4-metoksy-3-piperazin-1-yl- benzensulfonamid
ATE525362T1 (de) 2-(3-(4-(2-t-butyl-6-trifluormethylpyrimidin-4-